KLHL18 Inhibitors

KLHL18, a member of the Kelch-like family, is believed to be involved in protein ubiquitination processes, a presumption made based on the known roles of its close relatives. An understanding of ubiquitination becomes fundamental when discerning compounds that can influence KLHL18. MG132 and Bortezomib, proteasome inhibitors, act by preventing the degradation of ubiquitinated proteins. Their presence may disrupt the normal function of KLHL18 by creating a backlog of proteins awaiting degradation. Another interesting compound, MLN4924, specifically targets the NEDD8-activating enzyme. s. Compounds like Thalidomide and Lenalidomide modify ubiquitin ligase substrate recognition, thereby influencing the landscape of proteins being tagged for degradation. Given KLHL18's role, these compounds may alter its activity indirectly. PYR-41, IU1, and TAK-243 further emphasize the ubiquitin-proteasome system's intricacy. By inhibiting various components such as ubiquitin-activating enzymes and deubiquitinases, they can reshape the ubiquitination profile in a cell, influencing proteins like KLHL18.